I D
× COMMENTARYCOVER STORYIN THE NEWSNEWSFRONTSCHEMENTATOR + Show More
Chemical EngineeringChemenator Briefs
Flow Battery Honeywell Inc. (Charlotte, N.C.; www.honeywell.com) introduced a new…
BUSINESS NEWSTECHNICAL & PRACTICALFEATURE REPORT
Gear Pump Basics
The versatile nature of gear-pump technology allows operators to handle…
FACTS AT YOUR FINGERTIPSENVIRONMENTAL MANAGEREQUIPMENT & SERVICESAPPLIED TECHNOLOGIESFOCUSNEW PRODUCTS + Show More

Comment uncategorized

Evonik adds lipid production capacity to supply BioNTech vaccine manufacture

By Mary Page Bailey |

Evonik Industries AG (Essen, Germany) is investing in the short-term expansion of its specialty lipids production which are essential for mRNA-based COVID-19 vaccines. Commercial lipid quantities are to be produced at Evonik’s Hanau and Dossenheim sites in Germany as early as the second half of 2021 as part of a strategic partnership with vaccine manufacturer BioNTech. Evonik is making an important contribution to increasing the supply security of the Pfizer-BioNTech COVID-19 vaccine.  This follows the recent announcement that Merck would also be increasing its lipids production for the BioNTech vaccine.

“The pandemic requires decisive action,” says Christian Kullmann, chairman of Evonik’s executive board. “We are therefore doing everything possible to supply our partners with the critical lipids they need. At the same time, we are expanding our production capacity and competencies along the entire value chain.”

Lipids are fundamental to produce highly effective mRNA-based vaccines. Only with an increase in lipid supply can the volume of vaccine be further increased. This move marks an expansion of the strategic partnership between Evonik and the vaccine manufacturer BioNTech.

In mRNA-based vaccines, the mRNA is enclosed in a lipid nanoparticle (LNP) that is comprised of specific lipids. The LNP protects the mRNA and delivers it safely into the cell. There it is released so that the vaccine can exert its effect. Evonik has been a contract development and manufacturing organization (CDMO) leader for advanced drug delivery for many decades, supporting pharmaceutical companies worldwide in the development and production of complex parenteral drug products that require formulation technologies such as lipid nanoparticles. 

The Germany-based company is one of the few integrated development and manufacturing partners for cell and gene therapies, and has been actively involved in various mRNA-based vaccines projects for COVID-19.  

“With our partnership with BioNTech, we are systematically expanding our leading position as an integrated development partner in cell and gene therapies,” says Thomas Riermeier, head of Evonik’s Health Care business line. Evonik’s portfolio includes pharmaceutical excipients such as lipids, as well as CDMO services for the formulation development, GMP manufacturing and aseptic filling of complex parenteral drug products.”

Related Content

Chemical Engineering publishes FREE eletters that bring our original content to our readers in an easily accessible email format about once a week.
Subscribe Now
SICK Solutions for Cleaner Industries - Powerful Transitions
Gain a Digital Line of Sight Across the Whole Lifecycle of the Plant with a Digital Twin
Granulating High Viscous Melts in the Food Industry
How to Select a Pump for Industrial Applications
Temperature Instruments Improve Operations

View More